Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Recruiting now · Not applicable
Conditions studied: Chronic Graft Versus Host Disease
In brief
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD). The latter occurs in nearly 50% of patients and its pathogenesis remains poorly understood. Previous translational studies have delineated biological immune dysregulation involved in cGVHD and facilitated the development of new drug and therapeutic strategies. New aspects of T and B cells collaboration in the context of cGVHD using blood description of a key player called TFH, classicaly involved in germinal center reaction, were previously uncovered (Forcade et al, Blood 2016). Previous studies in the context of auto-immune inflammation (lupus nephritis) or organ transplant rejection, suggested that target tissue could contain accessory lymphoid structures (TLS). The description of such structures in cGVHD target tissue would give the opportunity to directly analyze immune key player involved the pathogenesis of cGVHD.
Key facts
- Study ID
- NCT06247150
- Run by
- University Hospital, Bordeaux
- People needed
- 70
- Starts
- 2024-05-21
- Expected to finish
- 2028-06-01
- Last updated by the study team
- 2026-07-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patient > 18 yo ;
- Having undergone an allogeneic stem cell tranplant ;
- 2 groups of patients will be eligible
- showing evidence of primary cGVHD or occuring after Donor Lymphocyte Infusion
- in the case of first occurrence of cGVHD, in the absence of any new systemic therapy ;
- in the case of recurrent cGVHD, steroid dose has to be below 15mg/day of Prednisone ;
- Having read, understood and signed an informed consent of the study;
- With social security affiliation;
You may not qualify if…
- Patient below 18 yo or unable to give consent ;
- Systemic therapy using steroids over 15mg/d of Prednisone ; and/or the use of other systemic agent introduced in the last month ;
- Haemorrhagic risk of biopsy anticipated ;
- Absence of patient agreement for the study
Where it is running
- CHU de Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire — Pessac, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.